AKBA / Akebia Therapeutics, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 AKEBIA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA THER

Filing Fee Table (filed herewith).

Calculation of Filing Fee Tables S-8 Akebia Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.00001 par value per share Other 18,900,000 $ 3.68 $ 69,552,000.00 0.0001531 $ 10,648.41 2

As filed with the Securities and Exchange Commission on August 7, 2025

S-8 As filed with the Securities and Exchange Commission on August 7, 2025 Registration No.

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.

Exhibit 99.1 Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ Da

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2025 AKEBIA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2025 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

Akebia Therapeutics, Inc. 2023 STOCK INCENTIVE PLAN (as amended by Amendment No. 1)

Exhibit 99.1 Akebia Therapeutics, Inc. 2023 STOCK INCENTIVE PLAN (as amended by Amendment No. 1) 1. Purpose The purpose of this 2023 Stock Incentive Plan (the “Plan”) of Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make impor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2025 AKEBIA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2025 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA THE

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product

Exhibit 99.1 Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance sheet and expanded institutional investor ownership through $50 million underwritten public

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.co

akebiatherapeuticsincvx Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance.

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Exhibit 99.1 Akebia Therapeutics Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) — Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of its underwritten public offering (the “Offering”) of 25,000,000 shares of

Underwriting Agreement, dated March 19, 2025, by and among the Company, Leerink Partners LLC and Piper Sandler & Co.

Exhibit 1.1 25,000,000 Shares AKEBIA THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.00001 PER SHARE UNDERWRITING AGREEMENT March 19, 2025 March 19, 2025 To the Representatives named in Schedule I hereto for the Underwriters named in Schedule II hereto Ladies and Gentlemen: Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2025 AKEBIA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2025 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissio

25,000,000 Shares Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281903 PROSPECTUS SUPPLEMENT (To Prospectus dated September 12, 2024) 25,000,000 Shares Common Stock We are offering 25,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Capital Market under the symbol “AKBA”. On March 19, 2025, the last reported sale price of our common stock on The Nasdaq Capital M

SUBJECT TO COMPLETION, DATED MARCH 19, 2025

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281903 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to

Compliance Policy

Exhibit 19.1 Akebia Therapeutics, Inc. Insider Trading Compliance Policy The Board of Directors of Akebia Therapeutics, Inc. (“Akebia” or the “Company”) has adopted this Insider Trading Compliance Policy (this “Policy”) to: •document its policies with respect to (i) transactions in the Company’s securities and the securities of companies with which the Company does business and (ii) the handling o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA THERAPEU

Product Agreement, dated August 29, 2017, by and between Keryx Biopharmaceuticals, Inc. and Patheon Inc. (an affiliate of Patheon Manufacturing Services LLC) related to the Master Manufacturing Services Agreement by and between Keryx Biopharmaceuticals, Inc. and Patheon Manufacturing Services LLC and certain of its affiliates dated November 12, 2016

Exhibit 10.78 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. WHITBY PRODUCT AGREEMENT (Ferric Citrate IR Tablets) This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agree

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$

Exhibit 99.1 Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million Cash resources and cash from operations expected to fund current operating plan for at least two years Akebia to Host Conferen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2025 AKEBIA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2025 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissio

Fourth Amended and Restated Non-Employee Director Compensation Program, effective January 27, 2025

Exhibit 10.18 AKEBIA THERAPEUTICS, INC. FOURTH AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Effective January 27, 2025 Non-employee members of the Board of Directors (the “Board”) of Akebia Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Fourth Amended and Restated Non-Employee Director Compensation Program (this

econd Amendment to Agreement for the Provision of a Loan Facility, dated February 3, 2025, by and between Akebia Therapeutics, Inc. and Kreos Capital VII

Exhibit 10.105 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. SECOND AMENDMENT TO AGREEMENT FOR THE PROVISION OF A LOAN FACILITY This SECOND AMENDMENT TO AGREEMENT FOR THE PROVISION OF A LOAN FACILITY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2025 AKEBIA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2025 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

As filed with the Securities and Exchange Commission on January 30, 2025

S-8 As filed with the Securities and Exchange Commission on January 30, 2025 Registration No.

Filing Fee Table (filed herewith).

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Akebia Therapeutics, Inc.

Form of Non-Officer Inducement Award Stock Option Agreement under 2023 Stock Incentive Plan

EX-99.2 Exhibit 99.2 AKEBIA THERAPEUTICS, INC. NON-OFFICER INDUCEMENT AWARD STOCK OPTION AGREEMENT Akebia Therapeutics, Inc. (the “Company”) hereby grants the following inducement non-statutory stock option award. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Number of shares of the Company’s Common Stock subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 AKEBIA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

1 Bettering the Lives of People Impacted by Kidney Disease John Butler, CEO January 2025 NASDAQ: AKBA Cautionary note on forward-looking statements Statements in this presentation regarding Akebia Therapeutics, Inc.’s (“Akebia’s”) strategy, plans, pr

1 Bettering the Lives of People Impacted by Kidney Disease John Butler, CEO January 2025 NASDAQ: AKBA Cautionary note on forward-looking statements Statements in this presentation regarding Akebia Therapeutics, Inc.

, by and among Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. and Averoa SA

Exhibit 10.4 AMENDMENT #1 TO LICENSE AGREEMENT This Amendment #1 (the “Amendment”) to the License Agreement (the “License Agreement”) dated December 22, 2022 by and between Akebia Therapeutics, Inc., a Delaware corporation with its principal place of business at 245 First Street, Cambridge, MA 02142 and its Subsidiary, Keryx Biopharmaceuticals, Inc. (“Keryx,” and collectively, “Akebia”), and Avero

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Exhibit 99.1 Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights •Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025 •Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for Vafseo •Vafseo granted TDAPA reimbursement and issued a Level

4, by and between the Company and STA Pharmaceutical Hong Kong Limited

Exhibit 10.5 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT #1 TO SUPPLY AGREEMENT This Amendment #1 (the “Amendment”) to the Supply Agreement dated February 10, 2021, by and between Akebia Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 AKEBIA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 22, 2024 AKEBIA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 22, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis Contract in place with a comprehensive kidney care provider serving more than 200,000 patients a

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis Contract in place with a comprehensive kidney care provider serving more than 200,000 patients at its thousands of U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2024 AKEBIA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

September 10, 2024

September 10, 2024 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Lauren Hamill Re: Akebia Therapeutics, Inc.

Form of Subordinated Note

Exhibit 4.10 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE

Form of Senior Note

Exhibit 4.9 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Akebia Therapeutics, Inc.

Form of Subordinated Indenture

Exhibit 4.8 AKEBIA THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314

Amended and Restated Open Market Sale Agreement, dated September

Exhibit 1.2 AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSM September 3, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares o

As filed with the Securities and Exchange Commission on September 3, 2024

As filed with the Securities and Exchange Commission on September 3, 2024 Registration No.

Form of Senior Indenture

Exhibit 4.7 AKEBIA THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act Section of Indenture of 1939, as amended 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Ina

mendment #1 to Second Amended and Restated License Agreement, dated Ma

Exhibit 10.3 CONFIDENTIAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Amendment #1 to the Second Amended and Restated License Agreement This Amendment #1 (the “Amendment”) to the Second Amended and Restated License A

CLPF-Cambridge Science Center, LLC and Akebia Therapeutics, Inc. dated May 6, 2024.

Exhibit 10.1 SEVENTH AMENDMENT TO LEASE This SEVENTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of May 6, 2024 (the “Effective Date”), by and between CLPF-CAMBRIDGE SCIENCE CENTER, LLC, a Delaware limited liability company (“Landlord”), and AKEBIA THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS A.MA-Riverview/245 First Street, L.L.C. (the “Original Landlord”) and Tena

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2024 AKEBIA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA THER

24, by and between the Company and Vifor (International) Ltd.

Exhibit 10.4 Confidential Execution Copy Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. TERMINATION AND SETTLEMENT AGREEMENT This TERMINATION AND SETTLEMENT AGREEMENT (this “Termination Agreement”) is entered into as of

Amendment #1 to Agreement for the Provision of a Loan Facility, dated July 10, 2024, by and between the Company and Kreos Capital VII (UK) Limited

Exhibit 10.5 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FIRST AMENDMENT TO AGREEMENT FOR THE PROVISION OF A LOAN FACILITY This FIRST AMENDMENT TO AGREEMENT FOR THE PROVISION OF A LOAN FACILITY, dat

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Exhibit 99.1 Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights •Vafseo® (vadadustat) Tablets market availability on track for January 2025 •TDAPA application submission and WAC pricing announcement for Vafseo complete •Second quarter 2024 Auryxia® (ferric citrate) net product revenues of $41.2 million Akebia to host conference call at 8:00 a.m. ET on

, by and between the Company and STA Pharmaceutical Hong Kong Limited

Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT #2 TO SUPPLY AGREEMENT This Amendment #2 (the “Amendment”) to the Supply Agreement by and between Akebia Therapeutics, Inc. (“Akebia”) and STA Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 10, 2024 AKEBIA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 10, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2024 AKEBIA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2024 AKEBIA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Akebia to host conference call at 8:00 a.m. ET on May 9

Exhibit 99.1 Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Akebia to host conference call at 8:00 a.m. ET on May 9 •Vafseo® (vadadustat) tablets FDA approved on March 27, 2024 •Vafseo launch activities underway with availability expected in January 2025 •Auryxia® (ferric citrate) net product revenues were $31.0 million for the first quarter 2024, A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 AKEBIA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission F

eparation Agreement with Ellen Snow, dated March 15, 2024

[Akebia Letterhead] Exhibit 10.11 March 15, 2024 By Email Ellen Snow [Address] Dear Ellen: This letter agreement (“Agreement”) confirms the terms of your separation from Akebia Therapeutics, Inc. (“Akebia” or the “Company”).1 Unless you rescind your assent as set forth in Section 5(viii) below, this Agreement shall be effective, final and binding upon the expiration of any applicable Revocation Pe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA THE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2024 AKEBIA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2024 AKEBIA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissio

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia Akebia’s Launch Stra

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia Akebia’s Launch Strategy Developed to Drive Toward a Potential New Oral Standard of Care Company to Host Conference Call on Thursday, March 28 at 8:00 AM ET CAMBRIDGE, Mass.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2024 AKEBIA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2024 AKEBIA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissio

Form of Officer Restricted Stock Unit Agreement under 2023 Stock Incentive Plan (Reflecting Clawback Policy)

Exhibit 10.46 AKEBIA THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENT FOR OFFICERS 2023 STOCK INCENTIVE PLAN Akebia Therapeutics, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2023 Stock Incentive Plan (the “Plan”). The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number o

February 2024 Amendment to Retention and Separation Agreement for Nicole R. Hadas

Exhibit 10.66 February 8, 2024 BY EMAIL Nicole R. Hadas [Address] Dear Nikki: Upon your execution of this Amendment, the following amendments will be made to your Separation Agreement with Akebia Therapeutics, Inc. (“Akebia”) dated May 5, 2022 (as previously amended, the “Separation Agreement”). Paragraph 1(ii) of the Separation Agreement shall be replaced in its entirety with the following: (ii)

Executive Severance Agreement

Exhibit 10.43 EXECUTIVE SEVERANCE AGREEMENT This EXECUTIVE SEVERANCE AGREEMENT (the “Agreement”) is entered into by and between Akebia Therapeutics, Inc., a Delaware corporation (“Akebia” or the “Company”), and , a resident of (the “Executive”), and is effective as of (the “Effective Date”). WHEREAS, Executive is a valued employee of the Company; and WHEREAS, the Company desires to provide certain

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA THERAPEU

Agreement under 2023 Stock Incentive Plan (Reflecting Clawback Polic

Exhibit 10.47 AKEBIA THERAPEUTICS, INC. OFFICER INDUCEMENT AWARD STOCK OPTION AGREEMENT Akebia Therapeutics, Inc. (the “Company”) hereby grants the following inducement non-statutory stock option award. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Number of shares of the Company’s Common Stock subject to this opt

January 29, 2024 by and between the Compa

Exhibit 10.103 Execution Version WARRANT AGREEMENT THIS WARRANT AGREEMENT (this “Agreement”), is made and entered into as of January 29, 2024 (the “Effective Date”), by and between Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), and Kreos Capital VII Aggregator SCSp (“Holder”). Recitals In order to induce Kreos Capital VII (UK) Limited (“Lender”) to enter into that certain Loan

Form of Officer Stock Option Agreement under 2023 Stock Incentive Plan (Reflecting Clawback Policy)

Exhibit 10.45 AKEBIA THERAPEUTICS, INC. STOCK OPTION AGREEMENT FOR OFFICERS 2023 STOCK INCENTIVE PLAN Akebia Therapeutics, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2023 Stock Incentive Plan (the “Plan”). The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Incentive Stock Option or No

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2024 AKEBIA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissio

Agreement for the Provision of a Loan Facility dated January 29, 2024 between the Company and Kreos Capital VII (UK) Limited

Exhibit 10.102 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AGREEMENT FOR THE PROVISION OF A LOAN FACILITY Dated January 29, 2024 (the “Closing Date”) Between KREOS CAPITAL VII (UK) LIMITED, and AKEB

Fourth Amendment to Loan Agreement dated as of October 31, 2023, by and among

Exhibit 10.93 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FOURTH AMENDMENT TO LOAN AGREEMENT This FOURTH AMENDMENT TO LOAN AGREEMENT (this “Amendment”), dated and effective as of October 31, 2023 (t

Form of Warrant

Exhibit 4.7 THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM

February 2024 Amendment to Retention and Separation Agreement for Michel Dahan

Exhibit 10.67 February 7, 2024 BY EMAIL Michel Dahan [Address] Dear Michel: Upon your execution of this Amendment, the following amendments will be made to your Separation Agreement with Akebia Therapeutics, Inc. (“Akebia”) dated May 5, 2022 (as previously amended, the “Separation Agreement”). Paragraph 1(ii) of the Separation Agreement shall be replaced in its entirety with the following: (ii) Se

Cash Bonus Agreement

Exhibit 10.44 [Date] Personal and Confidential [First Name Last name] [Address] Re: ELT Special Bonus Program Dear [First Name Last name]: I am pleased to offer you the opportunity to earn additional bonus payments related to your important work on the vadadustat program (the “ELT Special Bonus Program”) in recognition of your significant value to Akebia Therapeutics, Inc. (“Akebia” or the “Compan

Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights Potential vadadustat U.S. approval on PDUFA date of March 27, 2024 Strengthened balance sheet with $55.0 million term loan financing and $2

Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights Potential vadadustat U.

Akebia Therapeutics, Inc. Dodd-Frank Compensation Recovery Policy

Exhibit 97.1 Akebia Therapeutics, Inc. Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Akebia Therapeutics, Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated pursuant to Section 954 of the Dodd-F

Non-Employee Director Compensation Program, effective January

Exhibit 10.21 AKEBIA THERAPEUTICS, INC. THIRD AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Effective January 1, 2024 Non-employee members of the Board of Directors (the “Board”) of Akebia Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Third Amended and Restated Non-Employee Director Compensation Program (this “Pr

AKBA / Akebia Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Akebia Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 00972D105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is file

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2024 AKEBIA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

AKBA / Akebia Therapeutics, Inc. / Satter Muneer A Passive Investment

SC 13G/A 1 ff300441213ga2-satter.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Akebia Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 00972D105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Akebia Therapeutics, Inc.

As filed with the Securities and Exchange Commission on January 30, 2024

S-8 As filed with the Securities and Exchange Commission on January 30, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2024 AKEBIA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 AKEBIA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 AKEBIA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissi

Unlocking the Power of the Hypoxia- Inducible Factor (HIF) Pathway Delivering Innovation for Patients with Chronic Kidney Disease (CKD) January 2024 Nasdaq: AKBA 1 Statements in this presentation regarding Akebia Therapeutics, Inc.’s (“Akebia’s”) str

exhibit991presentation Unlocking the Power of the Hypoxia- Inducible Factor (HIF) Pathway Delivering Innovation for Patients with Chronic Kidney Disease (CKD) January 2024 Nasdaq: AKBA 1 Statements in this presentation regarding Akebia Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2023 AKEBIA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commis

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 21, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commis

Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights Akebia to host conference call at 8:00 a.m. ET

Exhibit 99.1 Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights Akebia to host conference call at 8:00 a.m. ET •Vadadustat NDA assigned a PDUFA date of March 27, 2024 •Vadadustat approved in 36 countries, including Australia and Taiwan •Akebia strengthens cash position modifying Pharmakon loan •Auryxia® (ferric citrate) quarterly net product revenue of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

October 2023 Amendment to Retention and Separation Agreement for Nicole R. Hadas

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 31, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease March 27, 2024 Set as User Fee Goal Date

Exhibit 99.1 Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease March 27, 2024 Set as User Fee Goal Date CAMBRIDGE, Mass.—October 25, 2023—Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the U.S. Food and Drug A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2023 AKEBIA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 6, 2023 AKEBIA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 6, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissi

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (D) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation or org

Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update

Exhibit 99.1 Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update CAMBRIDGE, Mass.—September 26, 2023—Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that Australia’s Therapeutic Goods Administration (TGA) has granted approval for Vafseo® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia associ

Form of Non-Employee Director Restricted Stock Unit Agreement under 2023 Stock Incentive Plan

Exhibit 10.12 AKEBIA THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENT FOR NON-EMPLOYEE DIRECTORS 2023 STOCK INCENTIVE PLAN Akebia Therapeutics, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2023 Stock Incentive Plan (the “Plan”). The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant

Form of Officer Restricted Stock Unit Agreement under 2023 Stock Incentive Plan

Exhibit 10.13 AKEBIA THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENT FOR OFFICERS 2023 STOCK INCENTIVE PLAN Akebia Therapeutics, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2023 Stock Incentive Plan (the “Plan”). The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number o

Form of Non-Employee Director Stock Option Agreement under 2023 Stock Incentive Plan.

Exhibit 10.10 AKEBIA THERAPEUTICS, INC. STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS 2023 STOCK INCENTIVE PLAN Akebia Therapeutics, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2023 Stock Incentive Plan (the “Plan”). The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Incentive Stoc

July 2023 Amendment to Retention and Separation Agreement for Nicole R. Hadas

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-363

License Agreement, dated May 24, 2023, by and between the Company and MEDICE Arzneimittel Pütter GmbH & Co. KG

CONFIDENTIAL Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. License Agreement By and Between Akebia Therapeutics, inc., and MEDICE Arzneimittel Pütter GmbH & Co. KG Dated May 24, 2023 CONFIDENTIAL TABLE OF

Form of Officer Inducement Award Stock Option Agreement under 2023 Stock Incentive Plan

Exhibit 10.14 AKEBIA THERAPEUTICS, INC. OFFICER INDUCEMENT AWARD STOCK OPTION AGREEMENT Akebia Therapeutics, Inc. (the “Company”) hereby grants the following inducement non-statutory stock option award. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Number of shares of the Company’s Common Stock subject to this opt

Second Amended and Restated Non-Employee Director Compensation Program, effective June 6, 2023.

Exhibit 10.8 AKEBIA THERAPEUTICS, INC. SECOND AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Effective June 6, 2023 Non-employee members of the Board of Directors (the “Board”) of Akebia Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Second Amended and Restated Non-Employee Director Compensation Program (this “Prog

Form of Officer Stock Option Agreement under 2023 Stock Incentive Plan

Exhibit 10.11 AKEBIA THERAPEUTICS, INC. STOCK OPTION AGREEMENT FOR OFFICERS 2023 STOCK INCENTIVE PLAN Akebia Therapeutics, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2023 Stock Incentive Plan (the “Plan”). The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Incentive Stock Option or No

Separation Agreement with David Spellman, dated June 9, 2023 and Amendment to Separation Agreement dated July 6, 2023

Exhibit 10.7 [Akebia Letterhead] June 9, 2023 BY EMAIL David Spellman Dear Dave: This letter agreement (“Agreement”) confirms the terms of your separation from Akebia Therapeutics, Inc. (“Akebia” or the “Company”).1 Unless you rescind your assent as set forth in Section 5(viii) below, this Agreement shall be effective, final and binding upon the expiration of any applicable Revocation Period set f

Form of May 2023 Amendment to Retention and Separation Agreement for Michel Dahan and Nicole R. Hadas

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA THER

Packaging Validation Transfer Agreement, dated April 20, 2023, by and between the Company and Otsuka Pharmaceutical Co. Ltd.

Exhibit 10.3 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Execution Version Confidential PACKAGING VALIDATION TRANSFER AGREEMENT This PACKAGING VALIDATION TRANSFER AGREEMENT (this “Agreement”) is entered into as of Ap

July 2023 Amendment to Retention and Separation Agreement for Michel Dahan

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.

, Biopharma Credit plc, BPCR Limited Partnership and Biopharma Credit Investments V (Master) LP

Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Execution Version THIRD AMENDMENT TO LOAN AGREEMENT This THIRD AMENDMENT TO LOAN AGREEMENT (this “Amendment”), dated and effective as of June 30, 2023 (the “Th

Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Akebia to host conference call on August 25, 2023 at 9:00 a.m. ET

Exhibit 99.1 Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Akebia to host conference call on August 25, 2023 at 9:00 a.m. ET •Expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis in Q3 2023 •Reports Auryxia® (ferric citrate) net product revenue of $42.2 million for Q2 2023 and reaffirms 2023 net

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2023 AKEBIA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2023 AKEBIA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissi

Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023 Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing

Exhibit 99.1 Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023 Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing CAMBRIDGE, Mass. – August 17, 2023 – Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 AKEBIA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissi

Akebia Therapeutics Provides Update on Form 10-Q Filing

Exhibit 99.1 Akebia Therapeutics Provides Update on Form 10-Q Filing •Akebia announces late filing of its second quarter earnings and Form 10-Q •Akebia reaffirms 2023 net product revenue guidance of $175 - $180 million •Akebia believes its cash resources as of June 30, 2023 will be sufficient to fund its current operating plan through at least the next twelve months •Akebia expects to resubmit NDA

SEC FILE NUMBER

SEC FILE NUMBER 001-36352 CUSIP NUMBER 00972D105 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2023 AKEBIA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2023 AKEBIA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023

Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023 CAMBRIDGE, Mass.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 9, 2023 AKEBIA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 9, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2023 AKEBIA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 7, 2023 AKEBIA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 7, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

Commercial Depth. Operational Excellence. A Commitment to Advance Innovation to Address Unmet Needs. John P. Butler, CEO June 2023 Exhibit 99.1 Statements in this presentation regarding Akebia Therapeutics, Inc.’s (“Akebia’s”) strategy, plans, prospe

exhibit991-jefferiesake Commercial Depth. Operational Excellence. A Commitment to Advance Innovation to Address Unmet Needs. John P. Butler, CEO June 2023 Exhibit 99.1 Statements in this presentation regarding Akebia Therapeutics, Inc.’s (“Akebia’s”) strategy, plans, prospects, expectations, beliefs, intentions and goals are forward- looking statements within the meaning of the U.S. Private Securi

As filed with the Securities and Exchange Commission on June 6, 2023

S-8 As filed with the Securities and Exchange Commission on June 6, 2023 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. 2023 Stock Incentive Plan

EX-99.1 Exhibit 99.1 Akebia Therapeutics, Inc. 2023 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2023 Stock Incentive Plan (the “Plan”) of Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2023 AKEBIA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

FDA Provides Akebia Therapeutics a Path Forward for Vadadustat

EX-99.1 Exhibit 99.1 FDA Provides Akebia Therapeutics a Path Forward for Vadadustat • FDA denies formal dispute resolution, but outlines path to resubmit NDA for dialysis-dependent patients without new clinical studies • Akebia plans to request Type A meeting and then resubmit NDA • Akebia will host a conference call on Tuesday, May 30 at 8:30 a.m. ET CAMBRIDGE, Mass.—May 30, 2023—Akebia Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2023 AKEBIA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia

Exhibit 99.1 Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia •Medice brings extensive expertise in nephrology and an established European dialysis business •Akebia to receive a $10 million upfront payment, potential for up to $100 million in comm

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

EX-99.1 Exhibit 99.1 Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement CAMBRIDGE, Mass.—May 22, 2023—Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Akebia has regaine

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 AKEBIA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2023 AKEBIA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2023 AKEBIA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA THE

Amendment No. 5 to Master Manufacturing Services and Supply Agreement, dated February 28, 2023, by and between Keryx Biopharmaceuticals, Inc. and Siegfried Evionnaz SA

Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT NO. 5 TO MASTER MANUFACTURING SERVICES AND SUPPLY AGREEMENT This Amendment No. 5 to Master Manufacturing Services and Supply Agreement (“Amendment No

Non-Employee Director Compensation Program, effective April

Exhibit 10.1 AKEBIA THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Effective April 27, 2023 Non-employee members of the Board of Directors (the “Board”) of Akebia Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compen

Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights Akebia to host conference call on May 8 at 8:30 a.m. ET

EX-99.1 Exhibit 99.1 Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights Akebia to host conference call on May 8 at 8:30 a.m. ET • Announced vadadustat is now approved in 32 countries following European Commission marketing authorization • Expects a response to Formal Dispute Resolution from FDA within next 30 days • Released positive top-line results fr

Form of Officer Stock Appreciation Rights Award Agreement under 2014 Incentive Plan

Exhibit 10.3 Name: [—] Number of Shares of Stock subject to SAR: [—] Base Value Per Share: $[—] Date of Grant: [—] OFFICER STOCK APPRECIATION RIGHTS AWARD granted under the AKEBIA THERAPEUTICS, INC. 2014 INCENTIVE PLAN STOCK APPRECIATION RIGHTS AGREEMENT This agreement (the “Agreement”) evidences a SAR granted by Akebia Therapeutics, Inc. (the “Company”) to the undersigned (the “Grantee”), pursuan

Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (001-36352), filed on April 28, 2023).

EX-3.1 Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF AKEBIA THERAPEUTICS, INC. SECTION 1 - STOCKHOLDERS Section 1.1. Place of Meetings. All meetings of stockholders of Akebia Therapeutics, Inc., a Delaware corporation (the “Corporation”), shall be held at such place, if any, as may be designated from time to time by the Board of Directors of the Corporation (the “Board of Directors”), the Chai

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2023 AKEBIA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2023 AKEBIA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 11, 2023 AKEBIA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 11, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

DEFR14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Termination and Settlement Agreement, dated December 22, 2022, by and between Keryx Biopharmaceuticals, Inc. and BioVectra Inc.

Exhibit 10.70 CONFIDENTIAL Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. TERMINATION AND SETTLEMENT AGREEMENT This termination and settlement agreement (the “Termination Agreement”) shall be effective

License Agreement, dated December 22, 2022, by and among Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. and Averoa SAS

Exhibit 10.81 CONFIDENTIAL Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LICENSE AGREEMENT by and among Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc., and Averoa SAS Dated as of December 2

Amendment No. 1 to Collaboration Agreement, dated December 2, 2022, by and between Akebia Therapeutics, Inc. and Mitsubishi Tanabe Pharma Corporation

Exhibit 10.53 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT NO.1 TO COLLABORATION AGREEMENT THIS AMENDMENT NO.1 TO COLLABORATION AGREEMENT (this “Amendment No. 1” ) is effective as of December 2, 2022 (the “E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA THERAPEU

Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights Akebia to host conference call on March 9 at 8:30 a.m. ET

EX-99.1 Exhibit 99.1 Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights Akebia to host conference call on March 9 at 8:30 a.m. ET • Receives positive CHMP opinion for Vafseo™ (vadadustat); anticipates potential Marketing Authorization in Europe in May 2023 • Reports Auryxia® (ferric citrate) net product revenue of $177.1M for 2022, an inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 9, 2023 AKEBIA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 9, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2023 AKEBIA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease

EX-99.1 Exhibit 99.1 Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease CAMBRIDGE, Mass.—February 21, 2023—Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received a second inter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2023 AKEBIA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

AKBA / Akebia Therapeutics Inc / Satter Muneer A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Akebia Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 00972D105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule

AKBA / Akebia Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Akebia Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 00972D105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fil

As filed with the Securities and Exchange Commission on January 30, 2023

S-8 As filed with the Securities and Exchange Commission on January 30, 2023 Registration No.

Filing Fee Table

EX-FILING FEES 4 d273172dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Akebia Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 AKEBIA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissi

A Commitment to Address Patients’ Unmet Needs

EX-99.1 Commercial Depth. Operational Excellence. A Commitment to Advance Innovation to Address Unmet Needs. John P. Butler, CEO David A. Spellman, CFO Mercedes Carrasco, IR & Corp Comm January 2023 Exhibit 99.1 Statements in this presentation regarding Akebia Therapeutics, Inc.’s (“Akebia’s”) strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements wi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2022 AKEBIA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commis

AKBA / Akebia Therapeutics Inc / Satter Muneer A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Akebia Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 00972D105 (CUSIP Number) December 8, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2022 AKEBIA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2022 AKEBIA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2022 AKEBIA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights Akebia to host conference call on November 3 at 4:30 p.m. ET

EX-99.1 Exhibit 99.1 Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights Akebia to host conference call on November 3 at 4:30 p.m. ET • Filed Formal Dispute Resolution Request related to the CRL for vadadustat • Reported Auryxia® (ferric citrate) quarterly net product revenue of $42.2, an increase of 14.9% over Q3 2021 • Affirmed 2022 Auryxia net product

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2022 AKEBIA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

Form of Amendment to Retention and Separation Agreement for Michel Dahan and Nicole R. Hadas

EX-10.2 2 exhibit102-formofformofame.htm EX-10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Exhibit 10.2 [Akebia Letterhead] November 2, 2022 By Email [First Name Last Name] [Address] Dear [First Name Last Name]: Up

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissio

Form of Officer Restricted Stock Unit Award Agreement under 2014 Incentive Plan (Retention Awards)

Exhibit 10.6 Officer Restricted Stock Unit Award granted under the AKEBIA THERAPEUTICS, INC. 2014 Incentive Plan Restricted Stock Unit Award Agreement This agreement (the ?Agreement?) evidences the grant of a restricted stock unit award by Akebia Therapeutics, Inc. (the ?Company?) to the undersigned (the ?Participant?), pursuant to and subject to the terms of the Akebia Therapeutics, Inc. 2014 Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA THER

Form of Officer Non-Statutory Stock Option Agreement under 2014 Incentive Plan (Retention Awards)

Name: [?] Number of Shares of Stock subject to Option: [?] Exercise Price Per Share: $[?] Date of Grant: [?] Officer Stock Option Award granted under the AKEBIA THERAPEUTICS, INC.

Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with COVID-19 and Hypoxemia (VSTAT)

Exhibit 99.2 Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with COVID-19 and Hypoxemia (VSTAT) CAMBRIDGE, Mass.?August 4, 2022? Akebia Therapeutics?, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of peop

Retention Agreement with David Spellman, dated June 22, 2022 (incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q (001-36352), filed on August 4, 2022)

Exhibit 10.5 [Akebia Letterhead] June 22, 2022 By Email David Spellman [Address] Dear Dave: I am pleased to offer you this Retention Agreement in recognition of your significant value to Akebia Therapeutics, Inc. (the ?Company?) and as an additional incentive for you to remain with the Company on the terms set forth below. 1. Retention Bonus. You will be eligible to receive a Retention Bonus pursu

Second Amendment and Waiver, dated July 15, 2022, by and among the Company, Biopharma Credit plc, BCPR Limited Partnership and Biopharma Credit Investments V (Master) LP

Exhibit 10.9 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. SECOND AMENDMENT AND WAIVER This SECOND AMENDMENT AND WAIVER (this ?Amendment and Waiver?), dated and effective as of July 15, 2022 (the ?Second Amendment Effe

Termination and Settlement Agreement, dated June 30, 2022, by and between the Company and Otsuka Pharmaceutical Co. Ltd (incorporated by reference to Exhibit 10.8 to the Company’s Quarterly Report on Form 10-Q (001-36352), filed on August 4, 2022)

Exhibit 10.8 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. TERMINATION AND SETTLEMENT AGREEMENT This TERMINATION AND SETTLEMENT AGREEMENT (this ?Agreement?) is entered into as of June 30, 2022 (the ?Termination Effecti

Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights Akebia to host conference call on August 4 at 4:30 p.m. ET

Exhibit 99.1 Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights Akebia to host conference call on August 4 at 4:30 p.m. ET ? Reported net Auryxia? (ferric citrate) product revenue of $43.7M, a 32.4% increase over Q2 2021 ? Increased 2022 net Auryxia product revenue guidance to $170 - $175M ? Regained full rights to vadadustat in the U.S., Europe and ot

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

AKBA / Akebia Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Akebia Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 00972D105 Date of Event Which Requires Filing of this Statement: May 31, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒

Termination of a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

Form of Retention and Separation Agreement for Michel Dahan and Nicole R. Hadas

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission F

Separation Agreement with Dell Faulkingham, dated May 5, 2022 (incorporated by reference to Exhibit 10.8 to the Company’s Quarterly Report on Form 10-Q (001-36352), filed on May 9, 2022)

Exhibit 10.8 [Akebia Letterhead] May 5, 2022 By Email Dell Faulkingham [Address] Dear Dell: This letter agreement (?Agreement?) confirms the terms of your separation from Akebia Therapeutics, Inc. (?Akebia? or the ?Company?).1 Unless you rescind your assent as set forth in Section 5(viii) below, this Agreement shall be effective, final and binding upon the expiration of any applicable Revocation P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA THE

Form of Officer Retention Letter Agreement

Exhibit 10.6 [Akebia Letterhead] [Date] By Email [First Name Last Name] Dear [First Name]: I am pleased to offer you this Retention Agreement in recognition of your significant value to Akebia Therapeutics, Inc. (the ?Company?) and as an additional incentive for you to remain with the Company on the terms set forth below. 1. Retention Bonus. You will be eligible to receive a Retention Bonus pursua

Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update

EXHIBIT 99.1 Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update ? Net Auryxia? (ferric citrate) product revenue of $41.4M, a 36% increase over Q1 2021 ? 2022 Net Auryxia product revenue guidance of $165?$170M ? Outlines refined strategic focus to deliver shareholder value ? Akebia to host conference call on Monday, May 9 at 4:30 p.m. ET CAMBRIDGE, Mass. ? May 9, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 7, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

, dated April 7, 2022, by and between Akebia Therapeutics, Inc. and Jefferies LLC (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K (001-36352), filed on April 7, 2022)

Exhibit 1.1 Execution Copy OPEN MARKET SALE AGREEMENTSM April 7, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Akebia Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Co

Costs Associated with Exit or Disposal Activities, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-253539 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 1, 2022) Common Stock This prospectus supplement supplements the sales agreement prospectus dated March 1, 2022 related to the offer and sale of shares of our common stock, $0.00001 par value per share, pursuant to the Amended and Restated Controlled Equity OfferingSM Sales Agreement, date

Akebia Therapeutics, Inc. Up to $26,000,000 Common Stock

Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-253539 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 1, 2022) Akebia Therapeutics, Inc. Up to $26,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, dated April 7, 2022, relating to the sale of shares of our common stock offered by this pro

Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Company to host conference call on Wednesday, March 30, 2022 at 6:00 p.m. ET

Exhibit 99.1 Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Company to host conference call on Wednesday, March 30, 2022 at 6:00 p.m. ET CAMBRIDGE, Mass.?March 30, 2022? Akebia Therapeutics?, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people i

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commissio

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 1, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36352 AKEBIA THERAPEU

Master Manufacturing Services Agreement by and between Keryx Biopharmaceuticals, Inc. and Patheon Manufacturing Services LLC and certain of its affiliates, dated September 27, 2016, and related Product Agreement dated September 27, 2016, and related Product Agreement dated October 12, 2016

Exhibit 10.58 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Triple asterisks denote omission. Master Manufacturing Services Agreement September 27, 2016 Table of Contents ARTICLE 14 STRUCTURE OF AGREEMENT AND INTERPRETATION4 1.1MASTER AGREEMENT. 4 1.2PR

Amendment No. 4 to Master Manufacturing Services and Supply Agreement, dated as of December 17, 2021, by and between Siegfried Evionnaz SA and Keryx Biopharmaceuticals, Inc.

EX-10.64 9 exhibit1064-amendment4toke.htm EX-10.64 Exhibit 10.64 AMENDMENT NO. 4 TO MASTER MANUFACTURING SERVICES AND SUPPLY AGREEMENT This Amendment No. 4 to Master Manufacturing Services and Supply Agreement (“Amendment No. 4”) is made effective and entered into on December 17, 2021 (the “Amendment Effective Date”) by and between Siegfried Evionnaz SA, with principal offices located at Route du

As filed with the Securities and Exchange Commission on March 1, 2022

POSASR 1 d269320dposasr.htm POSASR Table of Contents As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. 333-253539 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charte

Amended and Restated Cash Incentive Plan, effective January 19, 2022

Exhibit 10.28 AKEBIA THERAPEUTICS, INC. CASH INCENTIVE PLAN January 19, 2022 This Cash Incentive Plan (the ?Plan?) has been established to advance the interests of Akebia Therapeutics, Inc. (the ?Company?) by providing for the grant of Cash Incentive Awards to eligible employees of the Company and its subsidiaries. I. ADMINISTRATION The Plan will be administered by the Committee and its delegates

Investment Agreement between Akebia Therapeutics, Inc. and Vifor (International) Ltd., dated February 18, 2022

Exhibit 4.5 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. INVESTMENT AGREEMENT By and Between VIFOR (INTERNATIONAL) LTD. AND AKEBIA THERAPEUTICS, INC. Dated as of February 18, 2022 TABLE OF CONTENTS P

Assignment and Assumption Agreement, dated February 24, 2022, by and between Keryx Biopharmaceuticals, Inc. and Akebia Therapeutics, Inc.

Exhibit 10.11 ASSIGNMENT AND ASSUMPTION OF LEASE This Assignment and Assumption of Lease (the ?Assignment?) is made on February 24, 2022 (the ?Effective Date?) by and between KERYX BIOPHARMACEUTICALS, INC., a Delaware corporation (?Assignor?) and AKEBIA THERAPEUTICS, INC., a Delaware corporation (?Assignee?). Assignee and Assignor may be referred to from time to time in this Agreement individually

Power of Attorney of Ron Frieson

Exhibit 24.2 POWER OF ATTORNEY The undersigned director of Akebia Therapeutics, Inc. hereby constitutes and appoints John P. Butler and David A. Spellman, and each of them singly, his true and lawful attorneys-in-fact with full power to any of them, and to each of them singly, to sign for the undersigned and in his name in the capacity indicated below, the Post-Effective Amendment No. 1 to Registr

Calculation of Filing Fee Tables

Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment No. 1 to Form S-3 (Form Type) Akebia Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price

Collaboration Agreement between Akebia Therapeutics, Inc. and Mitsubishi Tanabe Pharma Corporation, dated December 11, 2015

CONFIDENTIAL Exhibit 10.49 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Triple asterisks denote omissions. COLLABORATION AGREEMENT BY AND BETWEEN AKEBIA THERAPEUTICS, INC. AND MITSUBISHI TANABE PHARMA CORPORATION CONFIDENTIAL TABLE OF CONTENTS Page ART

Second Amended and Restated License Agreement, dated February 18, 2022, by and between Akebia Therapeutics, Inc. and Vifor (International) Ltd.

Exhibit 10.54 CONFIDENTIAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omission. SECOND AMENDED AND RESTATED LICENSE AGREEMENT BY AND BETWEEN AKEBIA THERAPEUTICS, INC. AND VIFOR (INTERNATIONAL) LTD. Dated February 18, 2022 CONF

First Amendment to One Marina Park Drive Office Lease, dated February 24, 2022, by and between Keryx Biopharmaceuticals, Inc. and CLPF One Marina Park Drive LLC (successor-in-interest to Fallon Cornerstone One MPD LLC)

Exhibit 10.10 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this ?First Amendment?) is made as of February 24, 2022 (the ?Effective Date?), by and between CLPF ONE MARINA PARK DRIVE LLC (successor-in-interest to Fallon Cornerstone One MPD LLC), a Delaware limited liability company (?Landlord?), and AKEBIA THERAPEUTICS, INC. (successor-in-interest to Keryx Biopharmaceuticals, Inc.), a Del

, Biopharma Credit plc, BPCR Limited Partnership and Biopharma Credit Investments V (Master) LP

Exhibit 10.69 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FIRST AMENDMENT AND WAIVER This FIRST AMENDMENT AND WAIVER (this ?Amendment and Waiver?), dated and effective as of February 18, 2022 (the ?Effective Date?),

Akebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights

Exhibit 99.1 Akebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights ? Akebia is launch-ready pending FDA decision for vadadustat on PDUFA date, March 29, 2022 ? Amended agreement with Vifor Pharma Group strengthens collaboration for a successful commercial launch of vadadustat, if approved ? Net Auryxia product revenue of $142.2 million for 2

As filed with the Securities and Exchange Commission on March 1, 2022

POS AM 1 d257450dposam.htm POS AM Table of Contents As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. 333-253539 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter

Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch Agreement Leverages Vifor Pharma’s Exclusive Distribution Arrangement with Certain Dialysis Organizations Agreement Defines

Exhibit 99.1 Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch Agreement Leverages Vifor Pharma?s Exclusive Distribution Arrangement with Certain Dialysis Organizations Agreement Defines Profit Share Economics of Potential Vadadustat Revenue if Approved ? Vifor Pharma to make equity purchase of $20 million ? $40 million re

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 18, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commis

AKBA / Akebia Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0185-akebiatherapeuticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Akebia Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 00972D105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box t

As filed with the Securities and Exchange Commission on January 28, 2022

S-8 1 d235379ds8.htm S-8 As filed with the Securities and Exchange Commission on January 28, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-8756903 (State or other jurisdiction of incorporat

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 19, 2022 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2021 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commi

AKEBIA THERAPEUTICS, INC. Consolidated Statements of Operations (in thousands, except share and per share data) Three Months Ended Nine Months Ended September 30, 2021 September 30, 2020 September 30, 2021 September 30, 2020 Revenues: Product revenue

Exhibit 99.1 Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones ? Pre-commercialization activities underway in anticipation of March 29, 2022 PDUFA date ? Vadadustat marketing authorization application submitted to the European Medicines Agency ? Continued growth of Auryxia? (ferric citrate) with net product revenue of $36.8 million ? Company

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2021 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Commiss

Form of Officer Performance-Based Restricted Stock Unit Award (previously filed as Exhibit 10.2 to the Quarterly Report on Form 10-Q (File No. 001-36352) filed on November 4, 2021 and incorporated herein by reference).

Exhibit 10.2 Officer Performance-Based Restricted Stock Unit Award granted under the AKEBIA THERAPEUTICS, INC. 2014 Incentive Plan Performance-Based Restricted Stock Unit Award Agreement This agreement (the ?Agreement?) evidences the grant of a performance-based restricted stock unit award by Akebia Therapeutics, Inc. (the ?Company?) to the undersigned (the ?Participant?), pursuant to and subject

Form of Officer Cash Bonus Letter Agreement

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.